Skip to content
MarketScale
‹ Back to IndustriesSciences

Advocating for the Scientific Community Through Media

On the Space to Grow podcast, Astroscale’s Chris Blackerby and Charity Weeden bring their compelling experience and expertise to map out the technology, international policy, and scalability that will define the next generation of space exploration.   Looking at all aspects of the world of space and science is the crux of Space to Grow. It’s time to look at the human…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Chris Blackerby · AstroscaleCharity Weeden PodcastChris Blackerby PodcastEducation
Share

Key takeaways

01

On the Space to Grow podcast, Astroscale’s Chris Blackerby and Charity Weeden bring their compelling experience and expertise to map out the technology, international policy, and scalability that will define the next generation of space exploration.

02

Looking at all aspects of the world of space and science is the crux of Space to Grow.

03

It’s time to look at the human…

Get featured

Want to get featured in MarketScale Sciences?

Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required.

Request an invite

On the Space to Grow podcast, Astroscale’s Chris Blackerby and Charity Weeden bring their compelling experience and expertise to map out the technology, international policy, and scalability that will define the next generation of space exploration.

Looking at all aspects of the world of space and science is the crux of Space to Grow. It’s time to look at the human and storytelling aspect of science and space. Hosts Chris Blackerby and Charity Weeden of Astroscale welcomed MIT Engineer and Emmy-nominated science TV host Emily Calandrelli to the podcast. Calandrelli is a prominent member of the science communications ecosystem and shared her own story and insights on storytelling in science.

Becoming an engineer wasn’t a lifelong dream for Calandrelli—her drive was purely practical until discovering the technology and policy program in grad school at MIT. “It was looking at science and technology through a policy lens and asking about if it’s ethical, the role of government, and keeping the public safe. I thought these were fascinating questions,” she said.

That experience shifted her career to be more policy and communications driven. She intended to work in DC but got a call from a production company asking her if she wanted to host a TV show about space.

Years later, she’s a strong voice for the scientific community and advocates for people with all different talents to get involved in the space industry. “There are other ways to get involved in space outside of STEM,” she added.

Those types of roles are now trying to spread scientific literary and combat misinformation. Calandrelli focuses her approach on the human side of the story. She explained, “Going to the real human emotions attached to the story matters. You can frame an argument based on what the audience cares about and find simple, creative ways to explain science.”

Science is complex and uncertain, especially the coronavirus. In communicating a difficult and uncertain event, Calandrelli sees that science communication is challenging. “Everyone’s learning how to communicate this uncertainty, but there’s a lot of false information out there. It’s important to learn from the right sources,” she said.

Listen to Previous Episodes Here!

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

CB
Chris Blackerby

Follow Sciences Insights

Get new expert content in your inbox.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Roche pTau217 clearance and Labcorp’s Alzheimer’s test bring diagnostics to primary care

Roche pTau217 clearance and Labcorp’s Alzheimer’s test bring diagnostics to primary care

Recent advancements in Alzheimer’s pathology tests and lab automation are transforming diagnostics by moving the bottleneck from assay availability to workflow activation. These developments are making it feasible for primary care facilities to access cutting-edge diagnostic tools. This shift promises to enhance early detection and treatment strategies for Alzheimer's disease.

  • 01Lab automation is helping to remove bottlenecks in workflow activation for Alzheimer’s diagnostics.
  • 02Primary care facilities are gaining access to advanced Alzheimer’s diagnostic tests.
  • 03Early detection and treatment of Alzheimer's disease could be improved by these new diagnostic tools.

Aug 28, 2026

Genentech’s $750M Hillsboro build adds device fill-finish capacity by 2031

Genentech’s $750M Hillsboro build adds device fill-finish capacity by 2031

Genentech is investing $750 million in a new fill-finish plant in Hillsboro. The facility will focus on the production of prefilled syringes and autoinjectors. The site is expected to become operational in 2031.

  • 01Genentech is investing $750 million in a new Hillsboro facility.
  • 02The facility will produce prefilled syringes and autoinjectors.
  • 03Operations at the plant are expected to begin in 2031.

Aug 27, 2026

4basebio hpDNA in Genezen projects could cut AAV input DNA by 30%

4basebio hpDNA in Genezen projects could cut AAV input DNA by 30%

4basebio's cell-free hpDNA will be used by Genezen as starting material for viral vectors, potentially reducing the need for AAV input DNA by 30%. This innovation may lead to changes in the specification of plasmids and project timelines in gene therapy programs.

  • 01Genezen will utilize 4basebio’s cell-free hpDNA for viral vector production.
  • 02This approach could reduce AAV input DNA requirements by 30%.
  • 03The adoption of hpDNA could lead to changes in plasmid specification and project timelines.

Aug 27, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

CB
Chris Blackerby

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512